biopharmaceutical

Clinical-stage biotech Opus Genetics named to Fast Company's 2026 most innovative companies list for gene therapy work in inherited retinal diseases.

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

Quantum BioPharma closes $3.75M debenture offering and settles $1.12M debt through equity issuance, strengthening balance sheet for business development.

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.

Biodexa Pharmaceuticals executes 1-for-5 reverse ADR split effective April 6, 2026, to maintain Nasdaq listing compliance with minimum bid price requirements.

MediciNova executives to present clinical pipeline at March 2026 ROTH Conference, conducting direct investor meetings in Dana Point.

EyePoint grants stock options to six new employees as clinical program advances toward Phase 3 topline data for wet AMD therapy.

$IFRX received Nasdaq deficiency notice for failing $1 minimum bid price for 30 consecutive days. Company has until September 2026 to regain compliance or face delisting.

Minerva Neurosciences CEO to present at Stifel CNS Forum March 18, 2026, as company initiates Phase 3 roluperidone trial for schizophrenia treatment.

Quantum BioPharma revises debenture offering terms following share price decline, lowering conversion price to $3.00 and increasing warrant allocation.

Ascentage Pharma will report 2025 full-year unaudited results on March 25, 2026, with dual-language investor webcasts highlighting performance of its approved cancer therapies and clinical pipeline progress.

Beyond Air ($XAIR) will present at the 38th Annual Roth Conference in March, showcasing its nitric oxide therapy platform for respiratory and oncology applications.

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.

Quantum BioPharma raises capital through convertible debentures and debt-to-equity conversion to strengthen balance sheet and fund business development.

BioXcel Therapeutics raises $8M via direct offering of 4.5M shares at $1.739/share, with warrant modifications agreed, closing expected March 2026.

CSL announces $1.5 billion expansion of Illinois plasma facility with 300+ new jobs, operational by 2031, incorporating advanced Horizon 2 technology.

Kyntra Bio will report fourth quarter and full year 2025 financial results on March 16, 2026, as the biopharmaceutical company advances its oncology and rare disease pipeline.

Servier acquires Day One Biopharmaceuticals for $2.5B in cash, expanding rare pediatric oncology portfolio with closing expected Q2 2026.